共 269 条
[1]
Hochhaus A(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 917-927
[2]
Larson RA(2018)Comprehensive characterization of cancer driver genes and mutations Cell 173 371-385
[3]
Guilhot F(2017)The target landscape of clinical kinase drugs Science 358 6367-1098
[4]
Radich JP(2018)Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology JAMA Oncol 4 1093-464
[5]
Branford S(2017)Midostaurin plus chemotherapy for acute Myeloid leukemia with a FLT3 mutation N Engl J Med 377 454-607
[6]
Hughes TP(2018)Phase-IIb-study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML Blood 132 598-2528
[7]
Bailey MH(2018)A randomized phase III study of Ibrutinib (PCI-32765)-based therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN cancer research group (E1912) Blood 132 LBA-4A-2103
[8]
Tokheim C(2018)Ibrutinib regimens versus Chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-190
[9]
Porta-Pardo E(2019)Ibrutinib and Venetoclax for first-line treatment of CLL N Engl J Med 380 2095-2412
[10]
Sengupta S(2018)Chemotherapy-free combination of Obinutuzumab and Ibrutinib in first line treatment of follicular Lymphoma. The alternative study by the German low grade Lymphoma study group (GLSG) Blood 132 448-667